More than 7 million people would have gained coverage to the medicine, CMS said when it proposed the rule.
Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...
The Trump administration said Friday that Medicare and Medicaid won’t expand coverage of popular anti-obesity drugs, rejecting a proposal issued late last year by the Biden administration. The ...
The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, the Centers for Medicare and Medicaid Services said in a filing published ...
Investor's Business Daily on MSN24m
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss DrugsThe Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.
The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.
Medicare delays decision on obesity drug coverage, impacting millions of seniors and big weight-loss drugmakers like Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback